Halozyme Therapeutics Files Q3 2024 Report

TL;DR

**HALO filed its 10-Q for Q3 2024. All systems go on filings.**

AI Summary

Halozyme Therapeutics, Inc. filed its quarterly report for the period ended September 30, 2024. The company, incorporated in Delaware, is headquartered in San Diego, California, and its common stock trades on the Nasdaq under the ticker HALO. Halozyme has confirmed it has filed all required reports for the preceding 12 months and submitted all interactive data files.

Why It Matters

This filing provides investors with the latest financial and operational updates for Halozyme Therapeutics, crucial for assessing the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine quarterly filing confirming compliance with reporting requirements, not indicating new risks.

Key Players & Entities

• HALOZYME THERAPEUTICS, INC. (company) — Registrant
• September 30, 2024 (date) — Quarterly period ended
• Delaware (jurisdiction) — State of incorporation
• San Diego (location) — Principal executive office city
• HALO (ticker) — Common Stock Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange where common stock is registered

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market

Filing Documents

• halo-20240930.htm (10-Q) — 1385KB
• ex31110qq32024.htm (EX-31.1) — 13KB
• ex31210qq32024.htm (EX-31.2) — 13KB
• ex3210qq32024.htm (EX-32) — 14KB
• halo-20240930_g1.jpg (GRAPHIC) — 15KB
• halo-20240930_g2.jpg (GRAPHIC) — 1901KB
• halo-20240930_g3.jpg (GRAPHIC) — 1039KB
• 0001159036-24-000050.txt ( ) — 14799KB
• halo-20240930.xsd (EX-101.SCH) — 48KB
• halo-20240930_cal.xml (EX-101.CAL) — 82KB
• halo-20240930_def.xml (EX-101.DEF) — 256KB
• halo-20240930_lab.xml (EX-101.LAB) — 661KB
• halo-20240930_pre.xml (EX-101.PRE) — 460KB
• halo-20240930_htm.xml (XML) — 1274KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) - September 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income (Unaudited) - Three and Nine Months Ended September 30, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Nine Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows (Unaudited) - Nine Months Ended September 30, 2024 and 2023 6 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - Three and Nine Months Ended September 30, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 54

Controls and Procedures

Item 4. Controls and Procedures 54

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 55

Risk Factors

Item 1A. Risk Factors 55

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55

Other Information

Item 5. Other Information 55

Exhibits

Item 6. Exhibits 56

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except per share amounts) September 30, 2024 December 31, 2023 ASSETS Current assets Cash and cash equivalents $ 154,318 $ 118,370 Marketable securities, available-for-sale 511,988 217,630 Accounts receivable, net and contract assets 285,743 234,210 Inventories 131,412 127,601 Prepaid expenses and other current assets 43,515 48,613 Total current assets 1,126,976 746,424 Property and equipment, net 74,490 74,944 Prepaid expenses and other assets 80,151 17,816 Goodwill 416,821 416,821 Intangible assets, net 419,592 472,879 Deferred tax assets, net — 4,386 Total assets $ 2,118,030 $ 1,733,270 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 12,398 $ 11,816 Accrued expenses 96,417 100,678 Total current liabilities 108,815 112,494 Long-term debt, net 1,504,154 1,499,248 Other long-term liabilities 40,406 37,720 Deferred tax liabilities, net 11,952 — Total liabilities 1,665,327 1,649,462 Commitments and contingencies (Note 11) Stockholders' equity Preferred stock - $ 0.001 par value; 20,000 shares authorized; no shares issued and outstanding — — Common stock - $ 0.001 par value; 300,000 shares authorized; 127,183 and 126,770 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 127 127 Additional paid-in capital 61,886 2,409 Accumulated other comprehensive loss ( 6,939 ) ( 9,278 ) Retained earnings 397,629 90,550 Total stockholders' equity 452,703 83,808 Total liabilities and stockholders' equity $ 2,118,030 $ 1,733,270 See accompanying notes to condensed consolidated financial statements. 3 HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenues Royalties $ 155,061 $

View Full Filing

View this 10-Q filing on SEC EDGAR